Merck (NYSE: MRK ) recently announced positive Phase 1b clinical study results for its experimental Alzheimer's disease drug MK-8931. This compound belongs to a broader class of experimental Alzheimer's treatments called BACE inhibitors, and AstraZeneca (NYSE: AZN ) and Eli Lilly (NYSE: LLY ) have also explored drugs in this class. In the following video, health-care analyst Max Macaluso discusses the latest results, why shares of Merck didn't move significantly on the news, and also takes a look at the broader BACE inhibitor space.
If you're on the lookout for high-yielding stocks outside of the health-care sector, The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks. Grab your free copy today by clicking here.